MYDGF

Across TCGA pan-cancer cohorts, MYDGF mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MYDGF data layer compared with 23 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MYDGF mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MYDGF expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where MYDGF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.731	0.953	<.001	65	view →
LSCC	DFS	Median	II,III,IV	0.541	0.828	.017	16	view →
LUAD	OS	Median	II,III,IV	0.862	1.000	.004	10	view →
PDAC	DFS	Tertile	II,III,IV	0.812	0.723	.028	4	view →
GBM	DFS	Quartile	All	0.249	0.484	.005	3	view →
HNSC	OS	Quartile	II,III,IV	0.929	1.000	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MYDGF–CCRCC (OS)

Open the CCRCC breakdown →